Background/Aims: To determine the long-term efficacy of laparoscopic or robotic adenomyomectomy with or without gonadotropin-releasing hormone (GnRH) for the treatment of severely symptomatic adenomyosis. Methods: Between August 2008 and May 2011, we prospectively observed 33 patients who underwent laparoscopic or robotic adenomyomectomy with uterine artery ligation for the treatment of symptomatic adenomyosis. Seventeen patients (52%) received 3-course GnRH agonist treatment after the adenomyomectomy. Results: The mean operating time was 147.4 ± 52.0 min, and the mean blood loss was 36.1 ± 37.4 ml. Postoperative complications occurred in 5 patients, including 4 cases of febrile morbidity, 1 case of ileus and 1 case of pelvic abscess. Patients had statistically significant symptom relief during the 3-year follow-up period. Four of the 33 patients (12%) showed symptom relapse; 3 patients showed a relapse with dysmenorrhea and 1 patient showed a relapse with menorrhagia. There were no significant differences in terms of therapeutic outcomes between surgical-only and surgical-medical treatment. Conclusion: Laparoscopic or robotic adenomyomectomy was feasible and safe for women with severely symptomatic adenomyosis who requested uterine preservation. Moreover, this procedure provided long-term symptom control, regardless of postoperative GnRH agonist administration.

1.
Azziz R: Adenomyosis: current perspectives. Obstet Gynecol Clin North Am 1989;16:221-235.
2.
Garcia L, Isaacson K: Adenomyosis: review of the literature. J Minim Invasive Gynecol 2011;18:428-437.
3.
Wood C: Surgical and medical treatment of adenomyosis. Hum Reprod Update 1998;4:323-336.
4.
Brucker SY, Taran FA, Bogdanyova S, et al: Patient-reported quality-of-life and sexual-function outcomes after laparoscopic supracervical hysterectomy (LSH) versus total laparoscopic hysterectomy (TLH): a prospective, questionnaire-based follow-up study in 915 patients. Arch Gynecol Obstet 2014;290:1141-1149.
5.
Jo SH, Kim JM, Yoo WS, et al: Uterine myoma: treatment modalities and patient preference. Obstet Gynecol Sci 2008;51:1330-1336.
6.
Fujishita A, Masuzaki H, Khan KN, Kitajima M, Ishimaru T: Modified reduction surgery for adenomyosis. A preliminary report of the transverse H incision technique. Gynecol Obstet Invest 2004;57:132-138.
7.
Takeuchi H, Kitade M, Kikuchi I, et al: Laparoscopic adenomyomectomy and hysteroplasty: a novel method. J Minim Invasive Gynecol 2006;13:150-154.
8.
Kim JK, Shin CS, Ko YB, Nam SY, Yim HS, Lee KH: Laparoscopic assisted adenomyomectomy using double flap method. Obstet Gynecol Sci 2014;57:128-135.
9.
Wang PH, Liu WM, Fuh JL, Cheng MH, Chao HT: Comparison of surgery alone and combined surgical-medical treatment in the management of symptomatic uterine adenomyoma. Fertil Steril 2009;92:876-885.
10.
Liu WM, Chen CH, Chiu LH, Tzeng CR: Long-term follow-up of severely symptomatic women with adenomyoma treated with combination therapy. Taiwan J Obstet Gynecol 2013;52:85-89.
11.
Shwayder J, Sakhel K: Imaging for uterine myomas and adenomyosis. J Minim Invasive Gynecol 2014;21:362-376.
12.
Huskisson EC: Measurement of pain. Lancet 1974;2:1127-1131.
13.
Benagiano G, Brosens I, Lippi D: The history of endometriosis. Gynecol Obstet Invest 2014;78:1-9.
14.
Bird CC, McElin TW, Manalo-Estrella P: The elusive adenomyosis of the uterus - revisited. Am J Obstet Gynecol 1972;112:583-593.
15.
Guo J, Gao J, Yu X, Luo H, Xiong X, Huang O: Expression of DJ-1 and mTOR in eutopic and ectopic endometria of patients with endometriosis and adenomyosis. Gynecol Obstet Invest 2015;79:195-200.
16.
Sheng J, Zhang WY, Zhang JP, Lu D: The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception 2009;79:189-193.
17.
Bragheto AM, Caserta N, Bahamondes L, Petta CA: Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception 2007;76:195-199.
18.
Fedele L, Bianchi S, Raffaelli R, Portuese A, Dorta M: Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997;68:426-429.
19.
Pron G: New uterine-preserving therapies raise questions about interdisciplinary management and the role of surgery for symptomatic fibroids. Fertil Steril 2006;85:44-45; discussion 48-50.
20.
Phillips DR, Nathanson HG, Milim SJ, Haselkorn JS: Laparoscopic bipolar coagulation for the conservative treatment of adenomyomata. J Am Assoc Gynecol Laparosc 1996;4:19-24.
21.
Wang CJ, Yen CF, Lee CL, Soong YK: Laparoscopic uterine artery ligation for treatment of symptomatic adenomyosis. J Am Assoc Gynecol Laparosc 2002;9:293-296.
22.
Kim MD, Kim S, Kim NK, et al: Long-term results of uterine artery embolization for symptomatic adenomyosis. AJR Am J Roentgenol 2007;188:176-181.
23.
Smeets AJ, Nijenhuis RJ, Boekkooi PF, Vervest HA, van Rooij WJ, Lohle PN: Long-term follow-up of uterine artery embolization for symptomatic adenomyosis. Cardiovasc Intervent Radiol 2012;35:815-819.
24.
Taran FA, Stewart EA, Brucker S: Adenomyosis: epidemiology, risk factors, clinical phenotype and surgical and interventional alternatives to hysterectomy. Geburtshilfe Frauenheilkd 2013;73:924-931.
25.
Yu L, Wu T, Spain J, Li X, Wang W: Uterine artery embolization for the treatment of adenomyosis: questions for long-term efficacy. J Vasc Interv Radiol 2012;23:430-432.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.